Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A pharmacogenomics primer.

Michael H Court1

  • 1Comparative and Molecular Pharmacogenomics Laboratory, Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, USA.

Journal of Clinical Pharmacology
|August 1, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Linalool, linalyl acetate, and lavender essential oil: evaluation of metabolism and drug interactions using canine liver microsomes and recombinant enzymes.

Xenobiotica; the fate of foreign compounds in biological systems·2026
Same author

Should Injectable Meloxicam Be Approved for Use in Cats?

Journal of veterinary pharmacology and therapeutics·2026
Same author

Delayed postoperative hemorrhage (DEPOH) in an Irish Wolfhound with the <i>SERPINF2</i> c.605 T/T genotype: case description and variant prevalence across dog breeds.

Frontiers in veterinary science·2025
Same author

Canine duodenal organoids as a functional platform for intestinal CYP regulation and drug metabolism studies.

Drug metabolism and disposition: the biological fate of chemicals·2025
Same author

The association between injectable non-steroidal anti-inflammatory drugs and acute kidney injury in dogs and cats.

Veterinary anaesthesia and analgesia·2025
Same author

Avermectin-induced neurotoxicity and mortality reported more commonly in cats homozygous for ABCB11930_1931del TC after application of eprinomectin- versus selamectin-containing products.

Journal of the American Veterinary Medical Association·2025
Same journal

How to Replace the TQT Study-The Use of Concentration-QTc Modeling to Exclude a Small Effect of a Novel Drug on QT Interval: Historical Perspective and Implementation.

Journal of clinical pharmacology·2026
Same journal

Genome Sequencing Enhances Precision and Clinical Utility of Pharmacogenetic Data Compared to Arrays.

Journal of clinical pharmacology·2026
Same journal

FDA Gene Therapy Approvals (1998-2025): Current Status, Regulatory Evolution, and Future Directions.

Journal of clinical pharmacology·2026
Same journal

Human Disposition, Metabolism, and Excretion of Sevasemten (EDG-5506), a Selective Modulator of Fast Myosin in Healthy Volunteers.

Journal of clinical pharmacology·2026
Same journal

New Insights into Genetic Polymorphisms Influencing the Therapeutic Efficacy and Toxicity of Rivaroxaban.

Journal of clinical pharmacology·2026
Same journal

Physiologically Based Pharmacokinetic Modeling to Predict the Pharmacokinetics of Sacubitril/Valsartan in the Elderly with Renal or Hepatic Impairment Population.

Journal of clinical pharmacology·2026
See all related articles

Pharmacogenomic biomarkers identify genetic variants influencing drug response. This review explains pharmacogenomics principles and biomarker discovery for broader clinical adoption.

Area of Science:

  • Pharmacogenomics
  • Clinical Pharmacology
  • Biomarker Discovery

Background:

  • The Human Genome Project identified numerous genetic variants impacting drug response (pharmacogenomic biomarkers).
  • Routine clinical integration of pharmacogenomic testing remains limited.
  • Barriers include lack of trials, cost, ethical issues, and clinician unfamiliarity.

Purpose of the Study:

  • To provide clinical pharmacologists with a foundational understanding of pharmacogenomics.
  • To explain the principles and molecular mechanisms of pharmacogenomics.
  • To describe methods for discovering and applying pharmacogenomic biomarkers.

Main Methods:

  • Review of existing literature on pharmacogenomics.
  • Explanation of molecular mechanisms underlying pharmacogenomic variation.

Related Experiment Videos

  • Description of current biomarker discovery and clinical application strategies.

    • Main Results:

    • Identification of numerous pharmacogenomic biomarkers.
    • Understanding of principles and molecular mechanisms.
    • Description of methods for biomarker discovery and application.

    Conclusions:

    • Pharmacogenomics holds significant potential for personalized medicine.
    • Education and evidence generation are crucial for clinical adoption.
    • Further research is needed to overcome adoption barriers.